NCT06309628 is a clinical trial of Breathe sample in Lung Transplant Rejection, sponsored by Paragonix Technologies.

Who is sponsoring NCT06309628?

NCT06309628 is sponsored by Paragonix Technologies.

What drugs are being tested in NCT06309628?

Interventions in NCT06309628: Breathe sample.

What condition does NCT06309628 study?

NCT06309628 studies Lung Transplant Rejection.

Is NCT06309628 still recruiting?

NCT06309628 is currently terminated. Last updated 31 May 2025.

Last reviewed 2025-05-31 · How we verify

NCT06309628

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Analysis of Volatile Organic Compounds in the Breath of Lung Transplant Rejection Patients Using Infrared Spectroscopy

Terminated Last updated 31 May 2025

What this trial tests

trial testing Breathe sample in Lung Transplant Rejection in 35 participants. Terminated before completion.

Timeline

21 September 2023

Primary endpoint
9 May 2025

9 May 2025

Quick facts

Lead sponsor	Paragonix Technologies
Status	Terminated
Study type	OBSERVATIONAL
Enrollment	35
Start date	21 September 2023
Primary completion	9 May 2025
Estimated completion	9 May 2025
Sites	1 location across United States

Drugs / interventions tested

Breathe sample

Conditions studied

Lung Transplant Rejection — all drugs for Lung Transplant Rejection →

Sponsor

Paragonix Technologies — full company profile →

Who can join

18 and older, any sex, with Lung Transplant Rejection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will sample and analyze volatile organic compounds (VOCs) from participants considered to be at risk for developing rejection following lung transplant by using infrared spectroscopy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Lung Transplant Rejection

Currently open trials in the same condition.

NCT06824402 — Cryoprobe Biopsy and Chronic Rejection in Lung Transplant Recipients · NA · recruiting
NCT06399302 — Prospective Multicenter Research on Donor and Recipient Management Strategies to Improve Lung Transplant Outcomes · recruiting
NCT06112951 — A Prospective Randomized Trial of ECP in Subclinical AMR · NA · recruiting
NCT06082037 — A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfun · Phase 3 · recruiting
NCT06514378 — Safety of Endobronchial Mesenchymal Stromal Cells in the Treatment of Chronic Lung Allograft Dysfunction · Phase 1 · recruiting

Other Paragonix Technologies trials

Trials by the same sponsor.

NCT04930289 — Global Utilization And Registry Database for Improved preservAtion of doNor LUNGs · enrolling by invitation
NCT04141605 — Global Utilization And Registry Database for Improved heArt preservatioN · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06309628 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Paragonix Technologies
Last refreshed: 31 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06309628.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing